TEVA PHARMACEUTICALS
1
Name
Institution
TEVA PHARMACEUTICALS
2
Teva Pharmaceutical
Teva Pharmaceutical Industries is the largest manufacturer of generic pharmaceuticals.
The company thrives and grows in the competitive market of generic drugs. It has one main
competitive advantage that makes it able to compete and win: its operational expertise enables it
to produce generic pharmaceuticals faster and in bigger quantities than the competitors.
Teva Pharmaceuticals has many resources that help them grow and thrive. These include
research facilities, production equipment, a huge workforce, a number of plants across the world,
and entrepreneurial leaders. These resources are a necessary element in the growth that Teva has
experienced in recent years. The most valuable resources for Teva are production equipment,
workforce, research facilities, and its entrepreneurial leaders. These factors are very dynamic,
and Teva has managed to optimize on managing them well to their advantage. For example, they
have acquired some pharmaceutical companies thanks to their entrepreneurial leaders (Khanna,
Palepu & Bullock, 2013). Research has also enabled them stay in the market by rolling out new
products. Teva has a workforce that loves what they do and are important to the industry. They
enable Teva to research, produce, and distribute its genetic drugs worldwide.
Teva has the potential to make it big in innovative pharmaceuticals and biosimilars. The
vast research and development facilities and capital owned by the industry have made this
possible. They also work with some of the best researchers in the generic pharmaceutical
industry (Teva Pharmaceuticals, 2013). Biosimilars market has not been fully captured, and Teva
can be able to secure a leading position given their resources. In innovative pharmaceuticals,
Teva has a lot of potential. By conducting vast research and development, they can be able to
innovate or even come up with new drugs.
TEVA PHARMACEUTICALS
Teva has experienced tremendous growth in the recent past. This is great news but it has
a hard task at maintaining that growth and moving forward. To continue being competitive and
relevant in the market, Teva should diversify and start exploring pharmaceuticals that do not
have generics yet. These drugs include biologics that treat diseases like cancer. These drugs are
difficult to produce, but Teva has the capital and resources achieve this. Taking this step will
guarantee them a bright future in the pharmaceutical industry.
3
TEVA PHARMACEUTICALS
References
Khanna, T., Palepu, K. G., & Bullock, R. J. (2013). Winning in emerging markets: A road map
for strategy and execution. Boston, Mass: Harvard Business Press.
Teva Pharmaceuticals: Focusing on Generic, Specialty, and OTC Medicines. (January 01,
2013). Pharmacy Times, 79, 7.
4